Leipzig Adipose Tissue Childhood Cohort

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorUniversity of Leipzig

About this trial

In this study the investigators hypothesize that pathological alterations in adipose tissue biology already occur during the development and progression of obesity in children and adolescents. The investigators aim to identify and characterize mechanisms and molecular targets that affect the development of adipose tissue and ensuing obesity in childhood and adolescence.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

body weight: 3000 g - 180 kg

suitable surgical procedure

signed informed consent by the guardians and the study participant, if older 12 years

Disqualifiers

severe chronic and inflammatory diseases

acute or chronic infections

oncological diseases

clotting disorders

Trial population

children and adolescents undergoing surgery at the University Hospital Leipzig

Trial design

Design model

Cohort

Time perspective

Cross-sectional

Treatments tested in this trial

Not listed

Trial groups

1,000 Participants
are grouped into 1 trial group
Group A: lean and obese children and adolescents

Trial outcomes

Primary outcomes

1

Adipose tissue dysfunction

Adipose tissue dysfunction is assessed by evaluation of adipocyte size and number (hypertrophy vs. hyperplasia), adipocyte proliferation and differentiation, (lipid) cellular metabolism, inflammation, gene expression, fibrosis, and others; the association of AT dysfunction with clincial phenotype will be assessed

Time frame
10 years

Secondary outcomes

1

Presence of brown adipose tissue (BAT)

Adipose tissue samples will be evaluated for the presence of BAT on histological and molecular level and association with clinical phenotype will be investigated

Time frame
10 years
2

Inflammation of adipose tissue

Inflammation will be assessed by evaluating macrophage infiltration on histological and molecular expression level. Also, association with clinical phenotype will be assessed.

Time frame
10 years

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.